Taigen Biopharmaceuticals Holdings Ltd (4157) — Cash Flow Reinvestment Rate

Latest as of March 2025: 1.37x

Taigen Biopharmaceuticals Holdings Ltd (4157) has a Cash Flow Reinvestment Rate of 1.37x as of March 2025, reinvesting NT$91.67 Million (capex NT$874.00K plus investments NT$-90.80 Million) from operating cash flow of NT$67.16 Million. Explore Taigen Biopharmaceuticals Holdings Ltd capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

1.37x

(Capex + Investments) / Operating CF

Total Reinvested

NT$91.67 Million

Capex + Investments

Operating Cash Flow

NT$67.16 Million

TWD

Capital Expenditures

NT$874.00K

TWD

Taigen Biopharmaceuticals Holdings Ltd Cash Flow Reinvestment Rate (2021–2023)

Historical reinvestment intensity for Taigen Biopharmaceuticals Holdings Ltd across 2 annual periods. Also explore Taigen Biopharmaceuticals Holdings Ltd total assets for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Taigen Biopharmaceuticals Holdings Ltd (2021–2023)

Year-by-year capital reinvestment analysis for Taigen Biopharmaceuticals Holdings Ltd. For live market cap and broader valuation context, see market cap of Taigen Biopharmaceuticals Holdings Ltd.

Year	Reinvestment Rate	Total Reinvested (TWD)	Operating CF	Capex	YoY Change
2023	7.37x	NT$152.85 Million	NT$20.74 Million	NT$7.39 Million	▲ +1396.0%
2021	0.49x	NT$309.90 Million	NT$629.07 Million	NT$11.83 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow